Introduction
Somatic mutation profiling of breast tumor tissues has identified a number of distinct breast cancer molecular subtypes (1) (2) (3) characterised by diverse somatic mutations, including single nucleotide variants (SNVs) and copy number alterations (CNAs). The two most frequently mutated genes are TP53 and PIK3CA; however, a large number of other genes are less commonly mutated (4, 5) . Genes that show amplification include ERBB2, which can be treated with anti-HER2 agents such as trastuzumab, CCND1, FGFR1 and MYC (6) .
Targeted next generation sequencing (NGS) enables detection of low-frequency somatic mutations (i.e. SNVs detected at < 5%) in heterogeneous tumor populations and in circulating cell free DNA (cfDNA), when high coverage of >5000x (7, 8) is achieved, with the potential for guidance of treatment. However, current targeted NGS approaches that focus on key driver genes (e.g. TP53 and PIK3CA) do not fully capture genomic heterogeneity of breast cancer. Somatic CNA analysis has been carried out at the whole genome level, for example by single nucleotide polymorphism (SNP) 6.0 array (9) and low coverage sequencing (10) , and ERBB2 gene amplification has been investigated by real-time quantitative PCR and droplet digital PCR (ddPCR) (11) . As proof of concept, in this study we evaluated targeted NGS of cfDNA for analysis of mutations and amplification in 16 genes in 42 patients with metastatic breast cancer (MBC).
Materials and Methods

Patient samples, blood processing and DNA extraction
We recruited 42 patients with radiologically-confirmed MBC (study approved by the Riverside Research Ethics Committee ref 07/Q0401/20) (Supplemental Table 1 ) and 9 women attending for breast screening mammography as age matched controls (study participation. 20 ml venous blood was collected into EDTA-containing tubes (BD Biosciences) and 3 ml of the obtained plasma processed using the Circulating Nucleic Acids kit (Qiagen) as described previously (12) . DNA was isolated from 200 μ l buffy coat (for germ line DNA) and breast cancer cell lines (MDA-MB-231, MCF-7, SKBR3 and ZR-75-1)
as described previously (8) . Cancer antigen 15-3 (CA 15-3) results were obtained from patient notes.
Targeted next generation sequencing
We designed a custom 158 amplicon panel (size range 125-175 bp) across 16 genes (Supplemental Table 2 ) based on previous studies (6, 9) Ampliseq library preparation kit v2.0 as described previously (8) . A maximum of 6 libraries were pooled to achieve a coverage of at least 500x per amplicon.
Detection of SNVs and CNAs
Sequencing data was accessed through the Torrent Suite v4.2.0, reads aligned against hg19
using Alignment v4.0-r77189, and variants called using the coverageAnalysis v4.0-r77897 and variantCaller v4.0-r76860, respectively. VariantCaller was configured to call on high stringency somatic variants with down sampling set to 2000 and the hotspot_min_allele_frequency set to 0.01 to detect very low frequency (< 2%) variants.
Clinical Chemistry
C o n f i d e n t i a l COSMIC IDs were obtained using COSMIC v72 (13) . Each cfDNA sample was compared with paired lymphocyte DNA. ANNOVAR (14) was used to annotate all variants with refGene ID, functional consequence (e.g., non-synonymous), and functional predictions (using SIFT (15) , Polyphen-2 (16) and MutationTaster (17) (11) .
Droplet digital PCR
Digital droplet PCR (ddPCR) was used to validate TP53, PIK3CA and ESR1 mutations as described previously (8) . Primers and FAM-MGB probes were designed using Primer3 (22) for ERBB2, MYC, NOMO2, CCND1 and FGFR1 (Supplemental Table 3 Duplex assays were run with a RPPH1 (labelled with VIC-MGB) reference with 5 µl 1:10 dilution of pre-amplified cfDNA, 11 µl of 2x ddPCR Supermix for probes (Bio-Rad), 1.1 µl of both target and reference assays in a final volume of 20 µl as described previously (8) .
Statistical analysis
Survival analysis was performed using multiple Cox-regression as described previously (23) with each biomarker as a continuous time-dependent variable. The end of study date was selected as 01/12/2015. Comparison of total cfDNA concentrations (copies/ml) in patients with mutation or amplification compared to those without was by t-test.
Results
We detected the expected COSMIC mutations (PIK3CA p.E545K in MCF-7 and ZR75-1, and Tables 4 and 5 ). Dilution of the SKBR3 cell line into human genomic DNA (Roche) showed a limit of detection of 1% for TP53 p.R175H mutation and 10% for MYC and ERBB2 gene amplification, respectively (Supplemental Table   6 ). There was good agreement between results by NGS by ddPCR (Supplemental Figure 1 ).
Detection of mutations and gene amplification in cfDNA
We sequenced paired cfDNA and lymphocytes in 42 patients with metastatic breast cancer (40 ERα positive, 2 ERα negative, median age 55 y; range 25 -85 y; Supplemental Table 1) and 9 healthy female controls (median age 55 y; range, 37 -66 y). Mean coverage was over All variants reported were detected by variant caller, with one exception, a low-frequency ESR1 mutation in a serial sample from Patient 4. Exactly half the patients had 1 or more gene specific mutations and amplifications detected in cfDNA (mean = 2, range 1-6, Supplemental Table 7 , Figure 1A ). The top 3 mutated genes in cfDNA were ESR1, TP53 and PIK3CA
( Figure 1B ). Nine patients had 2 or more mutations detected and 10 patients had amplification in one or more genes (Supplemental Table 7 ). As validation, we compared NGS results with a smaller amplicon panel covering hotspot mutations in PIK3CA, TP53, ESR1, FGFR1 and FGFR2 (8) in 25 of the 42 patients. The same 9 mutations were identified across 6 patient samples and the VAFs were highly correlated (ρ = 0.9715; P < 0.0001; Figure 1C ). Mutation in the ESR1 gene was significantly associated with poorer overall survival ( Figure 1D ; hazard ratio (HR) 25.61; 95% CI 4.58 -143.18; P<0.0001, log-rank test), supporting a previous study (25) .
Nine patients had a HER2-positive primary tumor at diagnosis. Of these, 6 were progressing on anti-HER2 agents at the time of blood sampling and 4 had ERBB2 gene amplification in cfDNA, whereas 3 patients who were responding to their treatment had no evidence of ERBB2 gene amplification in cfDNA (Table 1) . One patient had HER2-positive metastatic
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C o n f i d e n t i a l biopsy and was stable on paclitaxel and herceptin at the time of blood sampling and was also negative for ERBB2 gene amplification in cfDNA. Lastly, 3 patients with a HER2 negative primary tumor had acquired ERBB2 gene amplification in cfDNA and all 3 were progressing at the time of the blood sample (Table 1) .
Dynamic changes in cfDNA on longitudinal follow-up.
We performed serial monitoring of alterations in cfDNA in 9 patients ( Table 2, 
Discussion
To our knowledge this is the first targeted NGS study of cfDNA to evaluate both somatic mutations and gene specific amplification in patients with MBC. (27), Safe-Seq (28) and BEAMing (29) have reported greater analytical sensitivity for mutation detection with variant allele fractions of <0.1%. While these approaches hold great promise, a major assumption is that ctDNA is either rare or absent in the healthy, cancer-free population. Demonstrating that a ctDNA marker has a diagnostic specificity close to 100% would also be important (30) . For clinical translation, detection of low-frequency variants must first be validated for CLIA/CAP/ISO-based precision testing. Of importance, each assay would need to be quality controlled using well-controlled reference standards (for example Horizon Discovery Quantitative Multiplex Reference Standards) to establish lower detection limits and reproducibility to detect variants at the lower limit.
Nine of the patients studied had more than one mutation detected in cfDNA, and in 7 patients these mutations were at different frequencies, indicating clonal differences in the origin of circulating tumor derived DNA. Importantly, 6 patients had an ESR1 mutation detected in cfDNA while on AI/endocrine therapy; this information could be used clinically to herald a change to chemotherapy. Ten patients had amplification in cfDNA in one or more genes, 3
patients had amplification only and 7 patients had both amplification and mutations. These data support heterogeneity of somatic alterations in breast cancer, with some characterised by mutations some by CNA and some by both. Ten patients had either a HER2-positive primary tumor or metastatic biopsy. Of these patients, 6 individuals had progressive disease at the time of blood sampling and 4 individuals had ERBB2 gene amplification in cfDNA, whereas ERBB2 gene amplification was undetected in 4 patients who were responding to an anti-HER2 agent. Importantly, 3 patients with a HER2 negative primary tumor had acquired
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C o n f i d e n t i a l ERBB2 gene amplification in cfDNA suggesting clonal evolution to a more aggressive phenotype (11, 31) . This information could be used clinically to change to an anti-HER2 therapy.
We performed serial monitoring in nine patients. Results demonstrate that cfDNA profiling of mutations and amplifications could provide useful data in terms of tumor heterogeneity, clonal evolution and response to treatment. Concentrations of circulating tumor DNA generally tracked with patient disease status, whereas when CA15-3 concentrations were high and generally remained increased. This supports the previous study by Dawson et al. (23) , who suggested that ctDNA to be a highly diagnostically sensitive biomarker of MBC.
Interestingly, in 3 patients we saw rising total cfDNA concentrations at a time when mutations in PIK3CA and/or TP53 and ESR1 either resolved or did not increase in circulating tumour DNA. A possible explanation for this is that another clone was shedding DNA into the blood that was not characterised by any of the alterations detectable by our NGS panel.
One approach to interrogate this would be to perform whole exome analysis of plasma cfDNA. Although we sequenced ~3500 COSMIC mutations and surveyed for amplification in 16 genes, the majority of cfDNA samples had less than 5 alterations detected, as has been shown in other studies using NGS mutation hot spot panels (32) . This is likely due to genomic heterogeneity as there are a large number of genes infrequently mutated in breast cancers (33, 34) . However, the targeted NGS approach used here has potential clinical utility, where for example, emergence of ERBB2 amplification in plasma cfDNA could signal a switch to an anti-HER2 therapy, and emergence of ESR1 mutations could indicate a switch away from endocrine therapy to standard chemotherapy. Overall, 9 patients (21%) could have been offered an alternative therapy if blood based monitoring was routine in the clinic. Our Table 2 for details). Treatments details are given above each graph. Table 2 for details). 
